NCT02958930

Safety and Efficacy of Transcranial Electromagnetic Treatment Against Alzheimer's Disease

Completed NA Last updated 23 April 2019

What this trial tests

NA trial testing MemorEM 1000 in Alzheimer Disease in 8 participants. Completed in 11 January 2019.

Timeline

1 October 2017

Primary endpoint
4 January 2019

11 January 2019

Quick facts

Lead sponsor	NeuroEM Therapeutics, Inc.
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	8
Start date	1 October 2017
Primary completion	4 January 2019
Estimated completion	11 January 2019
Sites	1 location across United States

Drugs / interventions tested

• MemorEM 1000

Conditions studied

• Alzheimer Disease — all drugs for Alzheimer Disease →
• Alzheimer Disease, Late Onset — all drugs for Alzheimer Disease, Late Onset →

Sponsor

NeuroEM Therapeutics, Inc.

Who can join

63 and older, any sex, with Alzheimer Disease or Alzheimer Disease, Late Onset. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to determine the safety and initial efficacy of Transcranial Electromagnetic Treatment (TEMT) in patients with mild/moderate Alzheimer's Disease. Throughout a 2-month treatment period, patients will be evaluated for cognitive performance, brain energy utilization, functional brain imaging, and blood/cerebrospinal fluid (CSF) markers for Alzheimer's Disease. Since all patients will receive TEMT, each patient's baseline measurements will serve as their own control for any treatment effects.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Alzheimer's disease drug development pipeline: 2019.
   Cummings J, Lee G, Ritter A, Sabbagh M, et al · · 2019 · cited 485× · PMID 31334330 · DOI 10.1016/j.trci.2019.05.008
2. Mitochondrial dysfunction in Alzheimer's disease: Role in pathogenesis and novel therapeutic opportunities.
   Perez Ortiz JM, Swerdlow RH. · · 2019 · cited 341× · PMID 30675901 · DOI 10.1111/bph.14585
3. A Clinical Trial of Transcranial Electromagnetic Treatment in Alzheimer's Disease: Cognitive Enhancement and Associated Changes in Cerebrospinal Fluid, Blood, and Brain Imaging.
   Arendash G, Cao C, Abulaban H, Baranowski R, et al · · 2019 · cited 31× · PMID 31403948 · DOI 10.3233/jad-190367
4. Transcranial Electromagnetic Treatment Stops Alzheimer's Disease Cognitive Decline over a 2½-Year Period: A Pilot Study.
   Arendash G, Abulaban H, Steen S, Andel R, et al · · 2022 · cited 13× · PMID 36005647 · DOI 10.3390/medicines9080042
5. Transcranial Electromagnetic Treatment "Rebalances" Blood and Brain Cytokine Levels in Alzheimer's Patients: A New Mechanism for Reversal of Their Cognitive Impairment.
   Cao C, Abulaban H, Baranowski R, Wang Y, et al · · 2022 · cited 11× · PMID 35585867 · DOI 10.3389/fnagi.2022.829049
6. Enhanced Brain Clearance of Tau and Amyloid-β in Alzheimer's Disease Patients by Transcranial Radiofrequency Wave Treatment: A Central Role of Vascular Endothelial Growth Factor (VEGF).
   Arendash GW, Lin X, Cao C. · · 2024 · cited 4× · PMID 39177605 · DOI 10.3233/jad-240600
7. The Brain Toxin Cleansing of Sleep Achieved During Wakefulness.
   Arendash GW. · · 2025 · cited 1× · PMID 39941597 · DOI 10.3390/jcm14030926
8. The Evidence That Brain Cancers Could Be Effectively Treated with In-Home Radiofrequency Waves.
   Arendash GW. · · 2025 · PMID 40867293 · DOI 10.3390/cancers17162665